Two new studies using CRISPR gene editing offer potential new treatments for Alzheimer's disease.
treatment, but there is so much more to be done," she said in an association news release.
CRISPR is shorthand for the Clustered Regularly Interspaced Short Palindromic Repeats system. Gene editing using this system is considered a powerful tool for identifying new potential medications. The study targeting this gene found levels of APOE-e4 could be significantly reduced in both miniature brains derived from an Alzheimer's patient as well as in humanized mouse models. It could do this without changing levels of other APOE variants that are thought to be neutral or protective.
Ornit Chiba-Falek, division chief of translational brain sciences at Duke, said the goal is to move towards precision medicine.In the other study, researchers developed a gene-editing strategy that targets the amyloid precursor protein . Study author Brent Aulston of the Subhojit Roy lab at University of California, San Diego calls APP “a gene with a central and indisputable role” in Alzheimer's.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Unborn Babies Use a Special Gene to Steal Nutrients From MumGenetic inheritance is a physical link that tethers our birth parents; one-half of two sets of chromosomes meshing together to form our own unique set of molecular instructions for life.
Consulte Mais informação »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Consulte Mais informação »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Consulte Mais informação »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Consulte Mais informação »
Acumen's Alzheimer's drug passes initial safety testAn experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety test and will advance to a larger trial, the company said on Sunday.
Consulte Mais informação »
Dear Abby: No one in my family visited my dad when he got Alzheimer’sDear Abby advises a man distraught that many of his relatives didn’t visit his father with Alzheimer’s.
Consulte Mais informação »